Autoimmune hemolytic anemia
MONDO:0020108Autoimmune hemolytic anemia (AIHA) is an autoimmune disorder in which various types of auto-antibodies are directed against red blood cells causing their survival to be shortened and resulting in hemolytic anemia.
Also known as: AHA, AIHA, Anemia, Hemolytic, Acquired Autoimmune, autoimmune haemolytic anemia, autoimmune hemolytic anemia, acquired autoimmune hemolytic anaemia, acquired autoimmune hemolytic anemia, anaemia hemolytic autoimmune
115 clinical trials for this condition and its sub-types, 49 tagged with Autoimmune hemolytic anemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Autoimmune hemolytic anemia
-
Autoimmune hemolytic anemia, warm type 29 trials
-
Evans syndrome 19 trials
-
Autoimmune hemolytic anemia, cold type 2 trials · 15 incl. sub-types
2 sub-types
- Cold agglutinin disease 14 trials
- Paroxysmal cold hemoglobinuria 0 trials
-
Neonatal autoimmune hemolytic anemia 0 trials
-
Can engineered immune cells tame autoimmune anemia?
Cure Recruiting nowThis early-stage trial is testing an experimental treatment called HY001N, a type of CAR-T cell therapy, in adults with autoimmune hemolytic anemia (AIHA) who have not improved after three or more standard treatments. The goal is to see if the therapy is safe and tolerable, and w…
Phase 1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Cure
Last updated Aug 07, 2026 00:00 UTC
-
New drug OM336 aims to tame overactive immune system
Disease control Recruiting nowThis early-phase trial tests a new drug called OM336 in 32 adults with autoimmune cytopenias, conditions where the immune system attacks blood cells. The study focuses on safety and how the drug moves through the body, not yet on curing the disease. Participants must have tried a…
Phase 1 • Sponsor: Lakefront Biotherapeutics West LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug rilzabrutinib aims to tame rare blood disorder
Disease control Recruiting nowThis study tests an oral drug called rilzabrutinib for warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system attacks red blood cells. About 90 adults who have not responded well to steroids will receive either rilzabrutinib or a placebo for 24 weeks, follo…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Experimental cell therapy targets tough blood cancers and anemia
Disease control Recruiting nowThis early-phase study is testing a new cell therapy called GT801 in 28 adults with relapsed or hard-to-treat B-cell blood cancers (like leukemia and lymphoma) or autoimmune hemolytic anemia (AIHA). The therapy uses a patient's own immune cells, modified to attack CD19-positive c…
Early phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New pill could tame rare blood disorder when other treatments fail
Disease control Recruiting nowThis study tests a daily pill called orelabrutinib for people with autoimmune hemolytic anemia (AIHA) that hasn't responded to standard treatments. AIHA is a condition where the immune system mistakenly attacks red blood cells, causing fatigue and anemia. The trial will enroll 50…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental mRNA CAR-T therapy targets autoimmune diseases in first human trial
Disease control Recruiting nowThis early-phase trial tests Arnovie101, an mRNA-based CAR-T therapy given directly into the bloodstream, in 5 people with lupus or autoimmune hemolytic anemia. The goal is to see if it is safe and how the body processes it. Researchers will also check if it reduces disease activ…
Early phase 1 • Sponsor: Circunited BioPharma (Shenzhen) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Engineered immune cells take on tough blood disorder
Disease control Recruiting nowThis early-stage study tests a new treatment for people with a severe type of autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior therapies. The treatment uses specially engineered immune cells (CAR-T cells) from a healthy donor to target and destro…
Early phase 1 • Sponsor: The Second Hospital of Anhui Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental CAR-T therapy targets tough autoimmune blood diseases
Disease control Recruiting nowThis early-stage study tests a new treatment called RD06-05, a type of CAR-T cell therapy, in 27 adults with autoimmune blood diseases like immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), or Evans syndrome. The therapy aims to control the disease by targeting a…
Early phase 1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New RNA therapy aims to tame Out-of-Control immune system
Disease control Recruiting nowThis early-stage study tests a new treatment called RXIM002 for people with severe autoimmune diseases that haven't responded to standard therapies. The treatment uses a special RNA molecule to create immune cells that target and destroy faulty B cells, which are causing the dise…
Early phase 1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Personalized immune cell therapy takes on lupus and MS
Disease control Recruiting nowThis early-stage trial tests a new treatment for people with autoimmune diseases like lupus and multiple sclerosis that haven't responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and destroy the faulty cells causing the d…
Phase 1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New antibody therapy targets stubborn autoimmune blood diseases
Disease control Recruiting nowThis study tests an experimental drug called CM336 in people with relapsed or refractory autoimmune cytopenia, including ITP and autoimmune hemolytic anemia. CM336 is a bispecific antibody designed to target and eliminate certain immune cells. The trial will enroll 158 adults to …
Phase 1/2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New 'Smart' immune therapy takes on lupus and arthritis
Disease control Recruiting nowThis early-phase study is testing a new drug called CC312 in 18 adults with severe autoimmune diseases like lupus and rheumatoid arthritis that haven't improved with standard treatments. CC312 is a type of immune therapy designed to target and destroy faulty B cells, similar to C…
Early phase 1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 26, 2026 18:43 UTC
-
Blood thinner breakthrough could stop clots in rare anemia
Prevention Recruiting nowThis study tests whether taking blood thinners for 12 weeks can prevent dangerous blood clots in people with autoimmune hemolytic anemia (AIHA), a rare disease where the immune system destroys red blood cells. About 72 adults with newly diagnosed or relapsed AIHA will receive eit…
Phase 2 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Prevention
Last updated Jun 27, 2026 08:06 UTC
-
Brain scans reveal hidden thinking problems in anemia patients
Knowledge-focused Recruiting nowThis study uses a non-invasive brain imaging technique called fNIRS to see how anemia affects thinking and memory. Researchers will measure brain activity in 323 adults with different types of anemia and compare it to cognitive test scores. The goal is to identify which brain reg…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Could a simple blood test predict clot risk in antiphospholipid syndrome?
Knowledge-focused Recruiting nowThis study asks whether autoimmune hemolytic anemia (AIHA) is linked to a higher risk of blood clots in people with antiphospholipid syndrome (APS). Researchers will compare the number of thrombotic events in APS patients who have AIHA versus those who do not. The study will enro…
Sponsor: New Valley University • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Scientists seek immune system clues from cancer patients and healthy volunteers
Knowledge-focused Recruiting nowThis research study collects blood, bone marrow, and tissue samples from people with cancer, blood disorders, and healthy volunteers. The goal is to study how the immune system changes during different treatments, including immunotherapy and chemotherapy. By comparing samples fro…
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Thousands with blood diseases to be tracked in massive chinese registry
Knowledge-focused Recruiting nowThis study is creating a large database of people in China with various blood diseases, such as leukemia, multiple myeloma, and hemophilia. Researchers will collect information from medical records and follow participants over time to learn about disease patterns, treatments, and…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
New french registry tracks rare blood disorders to improve care
Knowledge-focused Recruiting nowThis study is a national registry in France that collects information on adults newly diagnosed with immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA). It aims to describe how these diseases progress and how well treatments work in real life. Researchers will tr…
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC